Treatment costs for the group of patients with non-specific inflammatory bowel disease during acute exacerbation and further annual observation

Przeglad Gastroenterologiczny

Volumn 6, Issue 1, 2011, Pages 36-44

  Meder, Agnieszka ^a   Świa̧tkowski, Maciej ^a   Meder, Grzegorz ^b   Koza, Jarosław ^a   Szamocka, Małgorzata ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b University Hospital No 2 in Bydgoszcz   (Poland)

Author keywords

Non specific inflammatory bowel disease; Treatment costs

Indexed keywords

ARTICLE; BIOETHICS; BIOLOGICAL THERAPY; COST BENEFIT ANALYSIS; CROHN DISEASE; DATA BASE; DISEASE EXACERBATION; ENTERITIS; HEALTH CARE COST; HEALTH SERVICE; HOSPITALIZATION COST; HUMAN; MEDICAL CARE; POLAND; POSTOPERATIVE COMPLICATION; ULCERATIVE COLITIS;

EID: 79952507506     PISSN: 18955770     EISSN: 18974317     Source Type: Journal    
DOI: 10.5114/pg.2011.20106     Document Type: Article

References (34)

1. Feagan BG. Review article: economic issues in Crohn's disease-assessing the effects of new treatments on health-realted quality of life. Aliment Pharmacol Ther 1999; 13 (Suppl.4): 29-37. (Pubitemid 29446036)
2. Hall N, Rubin G, Hungin A, Dougall A. Medication beliefs among patients with inflammatory bowel disease who report low quality of life: a qualitative study. BMC Gastroenterology 2007; 7: 20.
3. Aliotta SL, Vlasnik JJ, Delor B. Enhancing adherence to longterm medical therapy: a new approach to assessing and treating patients. Adv Ther 2004; 21: 214-31. (Pubitemid 39524899)
4. Dezii CM. Medication noncompliance: what is the problem? Manag Care 2000; 9 (Suppl.): 7-12.
5. Binder V. Prognosis and quality of life in patients with ulcerative colitis and Crohn's disease. Int Disabil Stud 1988; 10: 172-4. (Pubitemid 19028028)
6. Blomqvist P, Ekbom A. Inflammatory bowel diseases: Health care and costs in Sweden in 1994. Scand J Gastroenterol 1997; 32: 1134-9.
7. Bernklev T, Jahnsen J, Henriksen M, et al. Relationship between sick leave, unemployment, disability, and health- related quality of life in patients with inflammatory bowel disease. Inflamm Bowel Dis 2006; 12: 402-12.
8. http://www.zus.pl/files/Absencja2006-2007.pdf
9. Hay AR, Hay JW. Inflammatory bowel disease: medical cost algorithms. J Clin Gastroenterol 1992; 14: 318-27.
10. Hay JW, Hay AR. Inflammatory bowel disease: costs of illness. J Clin Gastroenterol 1992; 14: 309-17.
11. Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004; 53: 1471-8. (Pubitemid 39265268)
12. Sewerynek E. Wpływ współpracy lekarza z pacjentem na efektywność leczenia osteoporozy. Terapia 2006; 3: 43-6.
13. Stewart MA. Effective physician-patient communication and health outcome: a review. CMAJ 1995; 152: (Suppl. 9): 1423-33.
14. Trummer UF, Mueller UO, Nowak P. Does physician-patient communication that aims at empowering patients improve clinical outcome? A case study. Patient Educ Couns 2006; 61: 299-306.
15. Yamada T. Aspekty psychospołeczne opieki nad pacjentami z chorobami przewodu pokarmowego. Podrȩcznik gastroenterologii (Małecka-Panas E. red. wyd. pol.). Czelej, Lublin 2006; 1-4.
16. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliksimab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9. (Pubitemid 34621118)
17. Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries and procedures in fistulizing Crohn's disease. Gastroenterology 2005; 128: 862-9. (Pubitemid 40523539)
18. Bernstein CN, Papineau N, Zajaczkowski J, et al. Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital. Am J Gastroenterol 2000; 95: 677-83.
19. Cohen RD. The cost of Crohn's disease: drug or surgery? Biodrugs 2000; 14: 331-244.
20. Feagan BG, Vreeland MG, Larson LR, Bala MV. Annual cost of care for Crohn's disease: A payor perspective. Am J Gastroenterol 2000; 95: 1955-60.
21. Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology 1999; 117: 49-57. (Pubitemid 29297619)
22. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Croh's disease. Gastroenterology 1990; 99: 956-63. (Pubitemid 20338451)
23. Tillinger W, Mittermaier C, Lochs H, et al. Health-related quality of life in patients with Crohn's disease: influence of surgical operation - a prospective trial. Dig Dis Sci 1999; 44: 932-8. (Pubitemid 29205603)
24. Jarnerot G, Hertervig E, Friis- Liby I, et al. Infliksimab as rescue therapy in severe to moderately severe ulcerative colitis: a randomised, placebo-controlled study. Gastroenterol 2005; 128: 1805-11. (Pubitemid 40824691)
25. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliksimab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76. (Pubitemid 41770166)
26. Kohn A, Daperno M, Armuzzi A, et al. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Aliment Pharmacol Ther 2007; 26: 747-56. (Pubitemid 47246204)
27. Feagan BG, Reinisch W, Rutgeerts P, et al. The effects of infliksimab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol 2007; 102: 794-802. (Pubitemid 46496629)
28. Reinisch W, Sandborn WJ, Bala M, et al. Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis. Inflamm. Bowel Dis 2007; 13: 1135-40. (Pubitemid 47402598)
29. Brooklyn T, Dunhill GS, Shetty A, et al. Infliksimab for the treatment of pyoderma gangrenosum: a randomised, double blind placebo controlled trial. Gut 2006; 55: 505-9.
30. Ljung T, Staun M, Grove O, et al. Pyoderma gangrenosum associated with Crohn's disease: effect of TNF alpha blockade with infliksimab. Scand J Gastroenterol 2002; 37: 1108-10.
31. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patient with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65. (Pubitemid 46108762)
32. MacIntosh DG, Lukas M, Sandborn W, et al. A randomised, double blind, placebo controlled trial of the clinical assessment of adalimumab safety and efficacy studied as an induction therapy in Crohn's disease. Gut 2004; 53 (Suppl. VI): A47.
33. Feagan BG, Panaccione R, Sandborn W, et al. An evaluation of adalimumab on the risk of hospitalization in patients with Crohn's disease, data from CHARM. Gastroenterology 2007; 132: A-513.
34. Feagan BG, Sandborn WJ, Hass S, et al. Health-Related Quality of Life During Natalizumab Maintenance Therapy for Crohn's Disease. Am J Gastroenterol 2007; 102: 2737-46. (Pubitemid 350179328)